PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTRATE CANCER RADIOTHERAPY
Award amount
$1,996,011Program and phase
SBIR · Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- L2 DIAGNOSTICS LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- GKA7VH5LFR25
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A vaccine targeting mosquito metabolic pathways to eradicate malaria
- PfAg, a multivalent peptide vaccine against malaria
- A Point of Care Test for Babesia microti
- Novel Diagnostic Biomarker Discovery and Validation for Malaria
- THERAPEUTIC VACCINE PLATFORM TO BOOST IMMUNE RESPONSES IN TUBERCULOSIS
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
84 SBIR/STTR records share this UEI (1999–2025). Reported award amounts total $45,551,124. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense